Experienced in Undifferentiated Pleomorphic Sarcoma

Dr. Dinesh Kapur

Hematology Oncology | Hematology | Oncology
Eastern Connecticut Hematology And Oncology Associates PC
330 Washington St, Suite 220, 
Norwich, CT 
Offers Telehealth
Experienced in Undifferentiated Pleomorphic Sarcoma
Eastern Connecticut Hematology And Oncology Associates PC
330 Washington St, Suite 220, 
Norwich, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dinesh Kapur is a Hematologist Oncology specialist and a Hematologist in Norwich, Connecticut. Dr. Kapur is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Childhood Iron Deficiency Anemia.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Hartford Hospital
William W Backus Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

EASTERN CONNECTICUT HEMATOLOGY AND ONCOLOGY ASSOCIATES PC
330 Washington St, Suite 220, Norwich, CT 06360

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Cobolimab, Dostarlimab, Docetaxel
Study Phase: Phase 3
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment
Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment
Enrollment Status: Terminated
Publish Date: September 13, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

1 Total Publications

Type 1 Autoimmune Pancreatitis Unmasked by COVID-19 Vaccine.
Type 1 Autoimmune Pancreatitis Unmasked by COVID-19 Vaccine.
Journal: ACG case reports journal
Published: June 07, 2022
Similar Doctors
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Daniel Y. Reuben
Hematology Oncology | Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Daniel Y. Reuben
Hematology Oncology | Hematology | Oncology

Hartford Healthcare Medical Group Specialists PLLC

1244 Storrs Rd, Road, 
Storrs, CT 
 (19.6 miles away)
860-724-2579
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Reuben is a Hematologist Oncology specialist and a Hematologist in Storrs, Connecticut. Dr. Reuben is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Melanoma, and Bone Tumor. Dr. Reuben is currently accepting new patients.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. William V. Walsh
Hematology Oncology | Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. William V. Walsh
Hematology Oncology | Hematology | Oncology

Umass Memorial Medical Group Inc

55 Lake Ave N, 
Worcester, MA 
 (53.6 miles away)
508-334-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Walsh is a Hematologist Oncology specialist and a Hematologist in Worcester, Massachusetts. Dr. Walsh is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Throat Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Bone Marrow Aspiration. Dr. Walsh is currently accepting new patients.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Ariel E. Birnbaum
Hematology Oncology | Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Ariel E. Birnbaum
Hematology Oncology | Hematology | Oncology

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (39.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ariel Birnbaum is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Birnbaum is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Rhabdomyosarcoma Embryonal, and Undifferentiated Pleomorphic Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kapur's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 56 Advanced Conditions
    View All 120 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile